Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glenzocimab in Acute Ischemic Stroke (GREEN)
NCT05559398Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2023
- Primary completion
- Jul 2025
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 3, randomised trial in ischemic stroke comparing Placebo with Glenzocimab (2 arms). Primary endpoint: Modified Rankin Scale at 90 days. Started Jan 2023; status: completed.
02
Drugs
glenzocimab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05559398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559398.